← All indications
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Drugs by status
Approved for this indication (44)
- necitumumab
- dacomitinib
- pralsetinib
- amivantamab-vmjw
- bevacizumab
- ensartinib
- adagrasib
- erlotinib
- vandetanib
- osimertinib
- lazertinib
- sunvozertinib
- ceritinib
- taletrectinib
- brigatinib
- icotinib
- entrectinib
- mobocertinib
- sotorasib
- vemurafenib
- Selpercatinib
- paclitaxel
- vinorelbine
- gefitinib
- alectinib
- pemetrexed
- durvalumab
- capmatinib
- docetaxel
- fam-trastuzumab deruxtecan-nxki
- +14 more
Phase 4 trials (35)
- caffeine
- modafinil
- pembrolizumab
- etoposide
- elemene
- atezolizumab
- furmonertinib
- dabrafenib
- cobicistat
- trametinib
- vitamin d3
- changchun marina
- multivitamins
- Filgrastim
- calcium
- midazolam
- carboplatin
- irinotecan
- tislelizumab
- cisplatin
- vinblastine
- penpulimab
- thalidomide
- propofol
- yangzhengxiaoji
- zoledronic acid
- sintilimab
- kanglaite
- risedronate
- anlotinib
- +5 more
Phase 3 trials (264)
Phase 2 trials (837)
Phase 1 trials (531)
- lyl797
- ca9hu-1
- rosuvastatin
- sgn-egfrd2
- interleukin-15
- mb1707
- soybean
- mgc026
- sct200
- ba1302
- loxo-260
- nxp900
- bbo-8520
- xzp-5809-tt1
- tt125-802
- apg-2449
- semi-allogeneic human fibroblasts
- arg1-18,19,20
- mov19-bbz car t cells
- cis-diamminedichloroplatinum
- gnr-051
- bpi-1178
- honokiol
- canertinib
- Exarafenib
- bivatuzumab
- sgn-cd47m
- bpi-442096
- hs-20093
- 99mtc ethylenedicysteine-deoxyglucose
- +501 more
Other trials (35)
- acetylcysteine
- eicosapentanoic acid
- lindera obtusiloba extract
- doxepin
- leuprolide
- aluminum hydroxide
- natalizumab
- berry polyphenols
- budesonide
- fpprgd2
- glycerol
- 18f-thymidine
- BMS-986192
- nvl-520
- iscar quercus
- varenicline
- docosahexaenoic acid
- oligo fucoidan
- ods2004436
- lisinopril
- urolithin a
- sheng bai
- motexafin lutetium
- shu yu wan
- sanguisorba officinalis l.
- 64cu-atsm
- 111in-j591
- gt201
- iohexol
- cyclin b1 peptide
- +5 more
Organizations
Organization Involved with Phase 4 Indications (50)
- Jiao Tong University
- Hacettepe University
- China Academy of Chinese Medical Sciences
- Simcere Pharmaceutical Co., Ltd
- Chinese Academy of Medical Sciences
- Celgene
- Zhejiang University
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Baotou Medical University
- ZonMw: The Netherlands Organisation for Health Research and Development
- University of Ferrara
- Betta Pharmaceuticals Co.,Ltd.
- Evangelisches Krankenhaus Hamm
- Nanjing Medical University
- National Guard Health Affairs
- Government of China
- Merck
- Henan Medical University
- Yan'an University Affiliated Hospital
- Hangzhou Normal University
- LanZhou University
- Guangdong Association of Clinical Trials
- Peking University
- Guangzhou Pharmaceucal Company Limited
- Hikma
- Wenzhou Medical University
- Chest Department, Taipei VGH
- Chang Gung University
- Johannes Gutenburg University
- Sichuan University
- +20 more
Organization Involved with Phase 3 Indications (345)
- Spanish Lung Cancer Group
- Universidad Autonoma de Barcelona
- Chonnam National University
- Universidad Autonoma de Madrid
- Immunotec Inc.
- Maastricht University
- Kindai University
- Henry Ford Health System
- European Lung Cancer Working Party
- Shanghai Municipal Science and Technology Commission
- Mayo Clinic
- PTS International Inc.
- University of Copenhagen
- Synta Pharmaceuticals Corp.
- University of Toronto
- Duke University
- University of Bergen
- Norwegian University of Science and Technology
- Chinese Thoracic Oncology Group
- Genzyme
- National Health and Medical Research Council, Australia
- Chinese University of Hong Kong
- Gruppo Oncologico Italiano di Ricerca Clinica
- University of South Florida
- Cancer and Leukemia Group B (CALGB)
- Mianyang Central Hospital
- Loxo Oncology
- First People's Hospital of Hangzhou
- McMaster University
- Telik
- +315 more
Organization Involved with Phase 2 Indications (587)
- Liaohe Oil Field General Hospital
- Government of Belgium
- Epimmune
- Hospital Clinico Lozano Blesa
- Hospital General Universitario de Castellón
- Benxi City hospital of Chinese medicine
- Owensboro Medical Health System
- Medigen Biotechnology Corporation
- Government of Colombia
- Oncolytics Biotech
- Guangdong Province Association Study of Thoracic Oncology
- Integrated Community Oncology Network
- MedPacto, Inc.
- Chroma Therapeutics
- Hellenic Cooperative Oncology Group
- Astex Pharmaceuticals, Inc.
- Chinese Lung Cancer Surgical Group
- Jeil Pharmaceutical Co., Ltd.
- GlobeImmune
- University of New South Wales
- Advaxis, Inc.
- American University of Beirut
- Haemato-Onkologische Praxis und Tagesklinik
- Iaso General Hospital, Athens
- ASL TO4, Chivasso
- Prologue Research International
- First Hospital of Shijiazhuang City
- AUSL della Romagna-RAVENNA
- American College of Radiology
- R-Pharm
- +557 more
Organization Involved with Phase 1 Indications (132)
- Checkmate Pharmaceuticals
- Nerium Biotechnology
- University of Leeds
- Viralytics
- Garden State Cancer Center
- Vasgene Therapeutics, Inc
- Mereo BioPharma
- Polyphenon E International,Inc.
- Guangdong Xiangxue Precision Medical Technology Co., Ltd
- Russian Academy of Medical Sciences
- Jiangxi Provincial Cancer Hospital
- National Institute for Health Research, United Kingdom
- Novella Clinical
- Zeno Pharmaceuticals
- Debiopharm
- Polaris Group
- Active Biotech AB
- Novotech
- Tracon Pharmaceuticals Inc.
- Worldwide Clinical Trials
- Nilogen Oncosystems
- Sheba Medical Center
- Center Trials & Treatment Inc.
- RefleXion Medical
- National Hospital Organisation Kyushu Cancer Centre
- Reata Pharmaceuticals, Inc.
- Centaurus Biopharma Co., Ltd.
- Hainan GeneralSanyang Pharmaceutical Co.,Ltd
- Tesaro
- Hospital Regional De Concepción
- +102 more
Organization Involved with Other Experimental Indications (18)
- Jiangnan University
- Pusan National University
- The First People's Hospital of Changzhou
- Changzhou No.2 People's Hospital
- Merus Labs
- Jiangsu Province Hospital
- Nantong University
- Hubei Mon Yan Pharmaceutical Co., Ltd
- Stemirna Therapeutics
- Beijing Sino-Japan Friendship Hospital
- Jiangyin People's Hospital
- Rijnstate Hospital
- Korea Institute of Oriental Medicine
- Sorlandet Hospital HF
- Beijing Yijiayi Medicine Techonoloy Co., Ltd.
- University of Groningen
- Qidong Gaitianli Medicines Co., Ltd
- Hi-Q Marine Biotech International, Ltd.